Prescribing of High‐Risk Medications for Older Adults with Rheumatic Disease
Arthritis & Rheumatology · 20.11.2026
DOI: 10.1002/art.70400 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 20.11.2026. Verfasst von Christine Anastasiou und 8 weiteren Autor:innen.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Background
Older adults with rheumatic diseases often experience multi‐morbidity and polypharmacy, potentially increasing their risk of adverse events from high‐risk medications (HRMs).
Objective
Evaluate the prevalence, characterize HRM prescriptions by prescriber characteristics, and identify patient‐level factors associated with HRM prescribing among older adults with rheumatic diseases.
Design
National cohort study using the American College of Rheumatology's Rheumatology Informatics System for Effectiveness (RISE) registry, linked to Medicare Parts A, B, and D.
Setting
Electronic health record‐based data from practices representing approximately one‐third of U.S. rheumatologists.
Participants
Medicare‐enrolled adults ≥65 years with ≥2 visits in 2021 at RISE participating practices and ≥2 ICD‐10 codes for selected rheumatic diseases.
Measurements
The primary outcome was prescription for a HRM. Logistic regression models were used to predict exposure to any HRM using generalized estimating equations to account for clustering of patients within practices.
Results
Among 45,455 older adults (mean age 75.8±6.4 years; 76.9% female), 13,977 (30.7%) received ≥1 HRM. Prescriptions predominantly originated from non‐rheumatology clinicians (82.3%). Common HRMs included skeletal muscle relaxants, first‐generation antihistamines, antidepressants with strong anticholinergic activity, non‐benzodiazepine benzodiazepine receptor agonist hypnotics (“Z‐drugs”), and antispasmodics. In adjusted analyses, patients with axial spondyloarthritis (OR 1.40, 95%CI 1.20‐1.62) and Sjögren's disease (OR 1.39, 95%CI 1.04‐1.86) had the highest odds of receiving a HRM compared with rheumatoid arthritis.
Conclusions
High‐risk medications are frequently prescribed to older adults with rheumatic diseases, exceeding the prevalence reported in the general Medicare population. These findings highlight the need for individualized medication review and enhanced cross‐specialty collaboration when managing this population.
Zitieren
APA
Anastasiou, C., Roberts, E., Costenbader, K. H., Stovall, R., Shiboski, S., Ciccarone, D., Steinman, M. A., Schmajuk, G., & Yazdany, J. (2026). Prescribing of High‐Risk Medications for Older Adults with Rheumatic Disease. Arthritis & Rheumatology. https://doi.org/10.1002/art.70400
Vancouver
Anastasiou C, Roberts E, Costenbader KH, Stovall R, Shiboski S, Ciccarone D, et al. Prescribing of High‐Risk Medications for Older Adults with Rheumatic Disease. Arthritis & Rheumatology. 2026. doi:10.1002/art.70400
BibTeX
@article{Anastasiou2026,
author = {Anastasiou, Christine and Roberts, Eric and Costenbader, Karen H. and Stovall, Rachael and Shiboski, Stephen and Ciccarone, Daniel and Steinman, Michael A. and Schmajuk, Gabriela and Yazdany, Jinoos},
title = {Prescribing of High‐Risk Medications for Older Adults with Rheumatic Disease},
journal = {Arthritis & Rheumatology},
year = {2026},
doi = {10.1002/art.70400}
}
EUVIMED